CHAMPIONS ONCOLOGY, INC. Income Tax Examination, Penalties and Interest Expense
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2025-04-30, per its 10-K filed 2025-07-23.
Financial Statements › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2025-07-23
- CHAMPIONS ONCOLOGY, INC. income tax examination, penalties and interest expense for the quarter ending 2025-04-30 was $0.00.
- CHAMPIONS ONCOLOGY, INC. income tax examination, penalties and interest expense for the quarter ending 2025-01-31 was $0.00.
- CHAMPIONS ONCOLOGY, INC. income tax examination, penalties and interest expense for the quarter ending 2024-10-31 was $0.00.
- CHAMPIONS ONCOLOGY, INC. income tax examination, penalties and interest expense for the quarter ending 2024-07-31 was $0.00.
- CHAMPIONS ONCOLOGY, INC. income tax examination, penalties and interest expense for fiscal 2025 was $0.00.
- CHAMPIONS ONCOLOGY, INC. income tax examination, penalties and interest expense for fiscal 2024 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 3 month | Income Tax Examination, Penalties and Interest Expense 6 month | Income Tax Examination, Penalties and Interest Expense 9 month | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|---|---|---|
| 2025-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23 | $0.00 derived: sum of 2 quarters · filed 2025-07-23 | $0.00 derived: sum of 3 quarters · filed 2025-07-23 | $0.00 10-K · filed 2025-07-23 |
| 2025-01-31 | $0.00 10-Q · filed 2025-03-17 | $0.00 derived: sum of 2 quarters · filed 2025-03-17 | $0.00 10-Q · filed 2025-03-17 | $0.00 derived: sum of 4 quarters · filed 2025-07-23 |
| 2024-10-31 | $0.00 10-Q · filed 2024-12-16 | $0.00 10-Q · filed 2024-12-16 | $0.00 derived: sum of 3 quarters · filed 2025-07-23 | $0.00 derived: sum of 4 quarters · filed 2025-07-23 |
| 2024-07-31 | $0.00 10-Q · filed 2024-09-13 | $0.00 derived: sum of 2 quarters · filed 2025-07-23 | $0.00 derived: sum of 3 quarters · filed 2025-07-23 | $0.00 derived: sum of 4 quarters · filed 2025-07-23 |
| 2024-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23 | $0.00 derived: sum of 2 quarters · filed 2025-07-23 | $0.00 derived: sum of 3 quarters · filed 2025-07-23 | $0.00 10-K · filed 2025-07-23 |
| 2024-01-31 | $0.00 10-Q · filed 2025-03-17 | $0.00 derived: sum of 2 quarters · filed 2025-03-17 | $0.00 10-Q · filed 2025-03-17 | |
| 2023-10-31 | $0.00 10-Q · filed 2024-12-16 | $0.00 10-Q · filed 2024-12-16 | ||
| 2023-07-31 | $0.00 10-Q · filed 2024-09-13 | |||
| 2023-01-31 | $0.00 10-Q · filed 2024-03-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $0.00 10-Q · filed 2024-03-15 | |
| 2022-10-31 | $0.00 10-Q · filed 2023-12-13 | $0.00 10-Q · filed 2023-12-13 | ||
| 2022-07-31 | $0.00 10-Q · filed 2023-09-13 | |||
| 2022-01-31 | $0.00 10-Q · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 10-Q · filed 2022-03-15 | |
| 2021-10-31 | $0.00 10-Q · filed 2023-03-16 | $0.00 10-Q · filed 2021-12-13 | ||
| 2021-07-31 | $0.00 10-Q · filed 2022-12-13 | |||
| 2021-01-31 | $0.00 10-Q · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 10-Q · filed 2022-03-15 | |
| 2020-10-31 | $0.00 10-Q · filed 2021-12-13 | $0.00 10-Q · filed 2021-12-13 | ||
| 2020-07-31 | $0.00 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |